Patents Assigned to Array Biopharma Inc.
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE
    Publication number: 20090131435
    Abstract: Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, W, and X are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 20, 2009
    Publication date: May 21, 2009
    Applicant: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • P38 inhibitors and methods of use thereof
    Patent number: 7521447
    Abstract: This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: April 21, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Mark Munson, David A. Mareska, Youngboo Kim, Robert D. Groneberg, James Rizzi, Martha Rodriguez, Ganghyeok Kim, Guy Vigers, Chang Rao, Devan Balachari, Darren Harvey
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7517994
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: April 14, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Heterocyclic inhibitors of MEK and methods of use thereof
    Patent number: 7511058
    Abstract: Disclosed are compounds of the Formula III and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 R10, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: March 31, 2009
    Assignee: Array BioPharma Inc.
    Inventors: T. Brian Hurley, Eli M. Wallace, Joseph P. Lyssikatos, James Blake
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 7501427
    Abstract: This invention concerns quinazoline analogs of Formula I: where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: March 10, 2009
    Assignee: Array BioPharma, Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • COMPOUNDS AND METHODS OF USE
    Publication number: 20090048224
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: September 5, 2008
    Publication date: February 19, 2009
    Applicants: Amgen, Inc., Array BioPharma, Inc.
    Inventors: Robert D. Groneberg, Benny C. Askew, JR., Derin C. D'Amico, James Zhan, Andras Toro, Youngboo Kim, David A. Mareska, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Chenguang Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Jeffrey Chen, Rana Nomak
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20090048279
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: October 10, 2008
    Publication date: February 19, 2009
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • RAF inhibitor compounds and methods
    Patent number: 7491829
    Abstract: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 17, 2009
    Assignees: Array Biopharma Inc., Genentech, Inc.
    Inventors: Ellen Laird, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse, Alan Olivero, George Topalov
  • Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
    Patent number: 7488823
    Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.
    Type: Grant
    Filed: November 10, 2003
    Date of Patent: February 10, 2009
    Assignee: Array Biopharma, Inc.
    Inventors: Eli Wallace, George Topolov, Qian Zhao, Joseph P. Lyssikatos
  • Bicyclic inhibitors of MEK and methods of use thereof
    Patent number: 7485643
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, R10, R20, R21, and R22 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: February 3, 2009
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, Joseph P. Lyssikatos, Hong Woon Yang
  • CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS
    Publication number: 20090012290
    Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.
    Type: Application
    Filed: September 12, 2008
    Publication date: January 8, 2009
    Applicant: ARRAY BIOPHARMA, INC.
    Inventors: Eli Wallace, George Topolov, Qian Zhao, Joseph P. Lyssikatos
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 7452895
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: November 18, 2008
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Heterocyclic Inhibitors of Mek and Methods of Use Thereof
    Publication number: 20080280957
    Abstract: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 17, 2006
    Publication date: November 13, 2008
    Applicants: ARRAY BIOPHARMA, INC., ASTRAZENECA AB
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hoog Woon Yang, James Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 7449486
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: November 11, 2008
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen R Laird, John Robinson, Shelley Allen
  • 8-Substituted Benzoazepines as Toll-Like Receptor Modulators
    Publication number: 20080234251
    Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.
    Type: Application
    Filed: August 17, 2006
    Publication date: September 25, 2008
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: George A. Doherty, C. Todd Eary, Robert D. Groneberg, Zachary Jones
  • N3 alkylated benzimidazole derivatives as MEK inhibitors
    Patent number: 7425637
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: September 16, 2008
    Assignee: Array BioPharma Inc.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • Compounds and methods of use
    Patent number: 7425631
    Abstract: Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 16, 2008
    Assignees: Amgen Inc., Array BioPharma Inc.
    Inventors: Robert D. Groneberg, Benny C. Askew, Jr., Derin C. D'Amico, James Zhan, Andras Toro, Youngboo Kim, David A. Mareska, Nianhe Han, Christopher H. Fotsch, Qingyian Liu, Babak Riahi, Kevin Yang, Aiwen Li, Chester Chenguang Yuan, Kaustav Biswas, Scott Harried, Thomas Nguyen, Wenyuan Qian, Jian Jeffrey Chen, Rana Nomak
  • N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
    Publication number: 20080177082
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: March 18, 2008
    Publication date: July 24, 2008
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley
  • N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
    Publication number: 20080171778
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: March 18, 2008
    Publication date: July 17, 2008
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Eli M. WALLACE, Joseph P. LYSSIKATOS, Allison L. MARLOW, T. Brian Hurley
  • N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
    Publication number: 20070299063
    Abstract: Disclosed are amino acid prodrugs of compounds of the formula I and pharmaceutically acceptable salts thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 14, 2007
    Publication date: December 27, 2007
    Applicant: Array BioPharma, Inc.
    Inventors: Eli Wallace, Joseph Lyssikatos, Allison Marlow, T. Hurley, Kevin Koch